Sabatolimab - Novartis Oncology
Alternative Names: AntiTIM-3 monoclonal antibody Novartis; MBG-453; NVP-MBG453Latest Information Update: 07 Oct 2024
At a glance
- Originator Novartis
- Developer Novartis; Novartis Oncology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Vaccines
- Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Glioblastoma; Myelodysplastic syndromes; Myelofibrosis; Solid tumours
Most Recent Events
- 07 Oct 2024 Discontinued - Phase-I for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA, Italy, Germany, Singapore, Spain (IV)
- 07 Oct 2024 Discontinued - Phase-I for Myelodysplastic syndromes (Combination therapy, Second-line therapy or greater) in USA, Italy, Germany, Singapore, Spain (IV)
- 20 Aug 2024 Novartis terminates phase-I trial in Myelodysplastic syndromes (Combination therapy, Second-line therapy or greater) and Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy) in Spain, Singapore, Germany, Italy, USA, Finland and Australia (PO) (NCT03940352)